PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?

Published:2019-12-10 Issue:8 Volume:42 Page:482-487
ISSN:1077-4114
Container-title:Journal of Pediatric Hematology/Oncology
language:en
Short-container-title:

Author:

Chen Sonja,Guenther Lillian M.,Aronhalt Amanda,Cardillo Lacey,Janeway Katherine A.,Church Alanna J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference30 articles.

1. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective;Wang;J Hematol Oncol,2017

2. Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database;Duchman;Cancer Epidemiol,2015

3. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials;Gelderblom;Eur J Cancer,2011

4. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects;Janeway;Lancet Oncol,2010

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRG4 represses the genesis and metastasis of osteosarcoma by inhibiting PDL1 expression;Tissue and Cell;2024-06

2. Identifying immune‐related prognostic biomarkers in osteosarcoma: Development and validation of the tumor immune microenvironment risk model based on analysis of TCGA;Environmental Toxicology;2024-03-11

3. PD-L1, STAT3, IL6, and EGFR Immunoexpressions in High-Grade Osteosarcoma;Advances in Orthopedics;2024-02-23

4. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies;MedComm;2023-07-10

5. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas;International Journal of Molecular Sciences;2023-05-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3